Moderna stock hits 52-week low at $30.7 amid market challenges
In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna stock target cut at BofA as key challenges persist
Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...
Moderna price target lowered to $34 from $41 at BofA
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...
Moderna, Inc. (NASDAQ:MRNA) Stake Lessened by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...
Why Moderna Inc. (MRNA) Crashed Last Week
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...
These 10 Firms Were Last Week’s Worst Performers
To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...
2 Biotech Stocks to Buy Hand Over Fist in February
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...